Cutler Group’s SpringWorks Therapeutics SWTX Stock Holding History

Cutler Group’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$4K	Buy	500 +100	+25%	+$4.62K	﹤0.01%	1657
2023 Q4	$3K	Buy	+400	New	+$10.4K	﹤0.01%	3006
2023 Q3	–	Sell	-2,000	Closed	-$5K	–	4312
2023 Q2	$5K	Buy	2,000 +1,100	+122%	+$28.9K	﹤0.01%	2652
2023 Q1	$1K	Buy	900 +100	+13%	+$2.92K	﹤0.01%	3570
2022 Q4	$1K	Sell	800 -7,000	-90%	-$172K	﹤0.01%	4165
2022 Q3	$32K	Buy	+7,800	New	+$224K	﹤0.01%	2249
2022 Q2	–	Sell	-42,700	Closed	-$79K	–	5655
2022 Q1	$79K	Buy	+42,700	New	+$2.44M	﹤0.01%	1881

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cutler Group's SWTX Position: Q1 2024 in Review

Cutler Group opened a new position in SpringWorks Therapeutics (SWTX) in Q1 2024: 810 shares worth $39K. The stake represents 0.01% of the portfolio and ranks #776 among its holdings. This is a return to the name: Cutler Group previously reported a position in SWTX as recently as Q2 2022.

Cutler Group first reported a position in SWTX in Q1 2022 and has held it in 3 quarters since. The position peaked at $81K in Q2 2022. 217 funds tracked by Wall St. Rank hold SWTX as of Q1 2024.

Cutler Group held 810 shares of SpringWorks Therapeutics worth $39K as of Q1 2024.
SpringWorks Therapeutics was a new Cutler Group position in Q1 2024.
SpringWorks Therapeutics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #776 holding.
Cutler Group first reported a position in SpringWorks Therapeutics in Q1 2022 and has held it in 3 quarters since.
Cutler Group's SpringWorks Therapeutics position peaked at $81K in Q2 2022.
217 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.